{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:43:57Z","timestamp":1792190637409,"version":"4.4.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T00:00:00Z","timestamp":1496102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01EO1503"],"award-info":[{"award-number":["01EO1503"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008454","name":"Boehringer Ingelheim Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008454","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Redox Biology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.redox.2017.06.009","type":"journal-article","created":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T20:02:08Z","timestamp":1498161728000},"page":"370-385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":276,"special_numbering":"C","title":["The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats"],"prefix":"10.1016","volume":"13","author":[{"given":"Sebastian","family":"Steven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Oelze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Hanf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swenja","family":"Kr\u00f6ller-Sch\u00f6n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Kashani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyer","family":"Roohani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Welschof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"G\u00f6dtel-Armbrust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huige","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl J.","family":"Lackner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Wojnowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge P.","family":"Bottari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Mayoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"M\u00fcnzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Daiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.redox.2017.06.009_bib1","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.redox.2017.06.009_bib2","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"E.-R. O. investigators, empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.redox.2017.06.009_bib3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.freeradbiomed.2005.06.018","article-title":"Oxidative stress and diabetic cardiovascular complications","volume":"40","author":"Jay","year":"2006","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.redox.2017.06.009_bib4","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1161\/01.RES.88.2.e14","article-title":"Mechanisms underlying endothelial dysfunction in diabetes mellitus","volume":"88","author":"Hink","year":"2001","journal-title":"Circ. Res."},{"key":"10.1016\/j.redox.2017.06.009_bib5","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1172\/JCI0214442","article-title":"Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite","volume":"109","author":"Zou","year":"2002","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.redox.2017.06.009_bib6","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1172\/JCI17786","article-title":"Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression","volume":"112","author":"Alp","year":"2003","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.redox.2017.06.009_bib7","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s001250051551","article-title":"Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus","volume":"43","author":"Heitzer","year":"2000","journal-title":"Diabetologia"},{"key":"10.1016\/j.redox.2017.06.009_bib8","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.2337\/db13-0577","article-title":"Peroxynitrite disrupts endothelial caveolae leading to eNOS uncoupling and diminished flow-mediated dilation in coronary arterioles of diabetic patients","volume":"63","author":"Cassuto","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.redox.2017.06.009_bib9","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.2337\/diabetes.51.11.3274","article-title":"Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy","volume":"51","author":"Forbes","year":"2002","journal-title":"Diabetes"},{"issue":"163\u2013170","key":"10.1016\/j.redox.2017.06.009_bib10","article-title":"Roles of the age-RAGE system in vascular injury in diabetes","volume":"902","author":"Yamamoto","year":"2000","journal-title":"Ann. N. Y Acad. Sci."},{"key":"10.1016\/j.redox.2017.06.009_bib11","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1681\/ASN.2008050514","article-title":"RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes","volume":"20","author":"Coughlan","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.redox.2017.06.009_bib12","doi-asserted-by":"crossref","first-page":"E685","DOI":"10.1152\/ajpendo.2001.280.5.E685","article-title":"Activation of NADPH oxidase by age links oxidant stress to altered gene expression via RAGE","volume":"280","author":"Wautier","year":"2001","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.redox.2017.06.009_bib13","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/35008121","article-title":"Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage","volume":"404","author":"Nishikawa","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.redox.2017.06.009_bib14","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1089\/ars.2012.4609","article-title":"Mitochondrial redox signaling: interaction of mitochondrial reactive oxygen species with other sources of oxidative stress","volume":"20","author":"Schulz","year":"2014","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.redox.2017.06.009_bib15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1089\/ars.2012.4953","article-title":"Molecular mechanisms of the crosstalk between mitochondria and NADPH oxidase through reactive oxygen species-studies in white blood cells and in animal models","volume":"20","author":"Kroller-Schon","year":"2014","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.redox.2017.06.009_bib16","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1161\/01.CIR.0000039325.03698.36","article-title":"RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice","volume":"106","author":"Bucciarelli","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.redox.2017.06.009_bib17","first-page":"F188","article-title":"Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia, American journal of physiology","author":"Rieg","year":"2014"},{"key":"10.1016\/j.redox.2017.06.009_bib18","doi-asserted-by":"crossref","first-page":"e112394","DOI":"10.1371\/journal.pone.0112394","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity","volume":"9","author":"Oelze","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.redox.2017.06.009_bib19","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S1262-3636(14)72689-8","article-title":"Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: a review of the clinical evidence","volume":"40","author":"Scheen","year":"2014","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.redox.2017.06.009_bib20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2337\/db12-1239","article-title":"Aging and insulin resistance: just say iNOS","volume":"62","author":"Evans","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.redox.2017.06.009_bib21","first-page":"92","article-title":"Jardiance (empagliflozin), an SGLT2 inhibitor, receives FDA approval for the treatment of patients with type 2","volume":"8","author":"Fala","year":"2015","journal-title":"Diabetes, Am. Health Drug Benefits"},{"key":"10.1016\/j.redox.2017.06.009_bib22","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"E.-R. O. t. investigators, Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.redox.2017.06.009_bib23","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"E. Investigators, Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.redox.2017.06.009_bib24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.redox.2017.06.009_bib25","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1124\/jpet.114.213454","article-title":"The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves beta-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat","volume":"350","author":"Hansen","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.redox.2017.06.009_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/DMSO.S58786","article-title":"Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet","volume":"7","author":"Vickers","year":"2014","journal-title":"Diabetes, Metab. Syndr. Obes.: Targets Ther."},{"key":"10.1016\/j.redox.2017.06.009_bib27","doi-asserted-by":"crossref","first-page":"e0147391","DOI":"10.1371\/journal.pone.0147391","article-title":"The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic beta-cell mass and glucose homeostasis in type 1 diabetes","volume":"11","author":"Cheng","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.redox.2017.06.009_bib28","doi-asserted-by":"crossref","first-page":"P247","DOI":"10.1055\/s-0034-1375104","article-title":"Effects of empagliflozin on oxidative stress and endothelial dysfunction in STZ-induced Type 1 diabetic rat","volume":"9","author":"Oelze","year":"2014","journal-title":"Diabetol. Stoffwechs."},{"key":"10.1016\/j.redox.2017.06.009_bib29","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.freeradbiomed.2008.05.009","article-title":"AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats","volume":"45","author":"Wenzel","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.redox.2017.06.009_bib30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/cvr\/cvs246","article-title":"Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition","volume":"96","author":"Kroller-Schon","year":"2012","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.redox.2017.06.009_bib31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/01.HYP.0000239207.82326.29","article-title":"Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats","volume":"48","author":"Oelze","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.redox.2017.06.009_bib32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000320627","article-title":"Vascular dysfunction in streptozotocin-induced experimental diabetes strictly depends on insulin deficiency","volume":"48","author":"Oelze","year":"2011","journal-title":"J. Vasc. Res."},{"key":"10.1016\/j.redox.2017.06.009_bib33","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/HYPERTENSIONAHA.113.01602","article-title":"Glutathione peroxidase-1 deficiency potentiates dysregulatory modifications of endothelial nitric oxide synthase and vascular dysfunction in aging","volume":"63","author":"Oelze","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.redox.2017.06.009_bib34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1530-0277.1986.tb05098.x","article-title":"Identification and selective precipitation of human aldehyde dehydrogenase isozymes using antibodies raised to horse liver aldehyde dehydrogenase isozymes","volume":"10","author":"McMichael","year":"1986","journal-title":"Alcohol., Clin. Exp. Res."},{"key":"10.1016\/j.redox.2017.06.009_bib35","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s00395-013-0386-5","article-title":"CD40L contributes to angiotensin II-induced pro-thrombotic state, vascular inflammation, oxidative stress and endothelial dysfunction","volume":"108","author":"Hausding","year":"2013","journal-title":"Basic Res Cardiol."},{"key":"10.1016\/j.redox.2017.06.009_bib36","first-page":"99","article-title":"Site-specific analysis of histone methylation and acetylation","volume":"287","author":"Umlauf","year":"2004","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.redox.2017.06.009_bib37","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/978-1-61779-316-5_15","article-title":"Native chromatin immunoprecipitation","volume":"791","author":"Cosseau","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.redox.2017.06.009_bib38","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/HYPERTENSIONAHA.114.04416","article-title":"Maternal treatment of spontaneously hypertensive rats with pentaerythritol tetranitrate reduces blood pressure in female offspring","volume":"65","author":"Wu","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.redox.2017.06.009_bib39","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/01.CIR.0000035650.05921.50","article-title":"Dual effect of ceramide on human endothelial cells: induction of oxidative stress and transcriptional upregulation of endothelial nitric oxide synthase","volume":"106","author":"Li","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.redox.2017.06.009_bib40","doi-asserted-by":"crossref","first-page":"44719","DOI":"10.1074\/jbc.M302836200","article-title":"Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of l-arginine metabolism to efficient nitric oxide production","volume":"278","author":"Lin","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.redox.2017.06.009_bib41","doi-asserted-by":"crossref","first-page":"E68","DOI":"10.1161\/hh1101.092677","article-title":"Phosphorylation of Thr(495) regulates Ca(2+)\/calmodulin-dependent endothelial nitric oxide synthase activity","volume":"88","author":"Fleming","year":"2001","journal-title":"Circ. Res."},{"key":"10.1016\/j.redox.2017.06.009_bib42","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2174\/156652412802480970","article-title":"Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db\/db mice","volume":"12","author":"Chen","year":"2012","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.redox.2017.06.009_bib43","doi-asserted-by":"crossref","first-page":"e100777","DOI":"10.1371\/journal.pone.0100777","article-title":"Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice","volume":"9","author":"Terami","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.redox.2017.06.009_bib44","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.2337\/diab.44.12.1447","article-title":"Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat","volume":"44","author":"Tokuyama","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.redox.2017.06.009_bib45","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1172\/JCI29103","article-title":"Islet beta cell failure in type 2 diabetes","volume":"116","author":"Prentki","year":"2006","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.redox.2017.06.009_bib46","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1124\/jpet.114.217992","article-title":"Analysis of the effect of canagliflozin on renal glucose reabsorption and progression of hyperglycemia in zucker diabetic Fatty rats","volume":"351","author":"Kuriyama","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.redox.2017.06.009_bib47","doi-asserted-by":"crossref","first-page":"e30555","DOI":"10.1371\/journal.pone.0030555","article-title":"Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models","volume":"7","author":"Liang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.redox.2017.06.009_bib48","doi-asserted-by":"crossref","first-page":"e0116851","DOI":"10.1371\/journal.pone.0116851","article-title":"Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes","volume":"10","author":"Watanabe","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.redox.2017.06.009_bib49","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.redox.2017.06.009_bib50","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1463-1326.2012.01569.x","article-title":"Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus","volume":"14","author":"Luippold","year":"2012","journal-title":"Diabetes, Obes. Metab."},{"key":"10.1016\/j.redox.2017.06.009_bib51","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/dc13-2338","article-title":"Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial","volume":"37","author":"Perkins","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.redox.2017.06.009_bib52","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.redox.2017.06.009_bib53","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/nm.2750","article-title":"Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy","volume":"18","author":"Bierhaus","year":"2012","journal-title":"Nat. Med"},{"key":"10.1016\/j.redox.2017.06.009_bib54","first-page":"207","article-title":"Deposition of advanced glycation end products (age) and expression of the receptor for age in cardiovascular tissue of the diabetic rat","volume":"79","author":"Sun","year":"1998","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.redox.2017.06.009_bib55","doi-asserted-by":"crossref","first-page":"7742","DOI":"10.1073\/pnas.91.16.7742","article-title":"Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications","volume":"91","author":"Wautier","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.redox.2017.06.009_bib56","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/bph.13517","article-title":"Targeting vascular (endothelial) dysfunction","volume":"174","author":"Daiber","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.redox.2017.06.009_bib57","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/bph.13403","article-title":"Crosstalk of mitochondria with NADPH oxidase via reactive oxygen and nitrogen species signalling and its role for vascular function","volume":"174","author":"Daiber","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.redox.2017.06.009_bib58","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/1358863X14568337","article-title":"Treatment effect with anti-RAGE F(ab')2 antibody improves hind limb angiogenesis and blood flow in Type 1 diabetic mice with left femoral artery ligation","volume":"20","author":"Tekabe","year":"2015","journal-title":"Vasc. Med."},{"key":"10.1016\/j.redox.2017.06.009_bib59","article-title":"Blockade of RAGE in Zucker obese rats with experimental periodontitis","author":"Grauballe","year":"2016","journal-title":"J. Periodontal Res."},{"key":"10.1016\/j.redox.2017.06.009_bib60","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice, American journal of physiology","volume":"306","author":"Vallon","year":"2014","journal-title":"Ren. Physiol."},{"key":"10.1016\/j.redox.2017.06.009_bib61","doi-asserted-by":"crossref","first-page":"F317","DOI":"10.1152\/ajprenal.00145.2014","article-title":"The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob\/ob type 2 diabetic mice with and without hypertension","volume":"307","author":"Gembardt","year":"2014","journal-title":"Am.\u00a0J. physiol. Ren. Physiol."},{"key":"10.1016\/j.redox.2017.06.009_bib62","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jdiacomp.2008.10.001","article-title":"Short- and long-term modulation of microvascular responses in streptozotocin-induced diabetic rats by glycosylated products","volume":"24","author":"Bassirat","year":"2010","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.redox.2017.06.009_bib63","article-title":"The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -\/- mice fed a western diet","author":"Han","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.redox.2017.06.009_bib64","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1124\/jpet.108.143966","volume":"328","author":"Thomas","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.redox.2017.06.009_bib65","doi-asserted-by":"crossref","first-page":"592760","DOI":"10.1155\/2010\/592760","article-title":"Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)","volume":"2010","author":"Ferreira","year":"2010","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.redox.2017.06.009_bib66","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/bph.12176","article-title":"Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats","volume":"169","author":"Apaijai","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.redox.2017.06.009_bib67","doi-asserted-by":"crossref","first-page":"103731","DOI":"10.1155\/2013\/103731","article-title":"A novel rat model of type 2 diabetes: the Zucker fatty diabetes mellitus ZFDM rat","volume":"2013","author":"Yokoi","year":"2013","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.redox.2017.06.009_bib68","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.redox.2017.06.009_bib69","doi-asserted-by":"crossref","first-page":"8306","DOI":"10.1073\/pnas.122225199","article-title":"Identification of the enzymatic mechanism of nitroglycerin bioactivation","volume":"99","author":"Chen","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.redox.2017.06.009_bib70","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1172\/JCI200419267","article-title":"Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance","volume":"113","author":"Sydow","year":"2004","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.redox.2017.06.009_bib71","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1074\/jbc.M606477200","article-title":"Role of reduced lipoic acid in the redox regulation of mitochondrial aldehyde dehydrogenase (ALDH-2) activity. Implications for mitochondrial oxidative stress and nitrate tolerance","volume":"282","author":"Wenzel","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.redox.2017.06.009_bib72","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1126\/science.1158554","article-title":"Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart","volume":"321","author":"Chen","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.redox.2017.06.009_bib73","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2119\/molmed.2010.00114","article-title":"Inhibition of aldehyde dehydrogenase 2 by oxidative stress is associated with cardiac dysfunction in diabetic rats","volume":"17","author":"Wang","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.redox.2017.06.009_bib74","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/cvr\/cvn182","article-title":"Manganese superoxide dismutase and aldehyde dehydrogenase deficiency increase mitochondrial oxidative stress and aggravate age-dependent vascular dysfunction","volume":"80","author":"Wenzel","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.redox.2017.06.009_bib75","doi-asserted-by":"crossref","first-page":"32554","DOI":"10.1038\/srep32554","article-title":"NOX2 amplifies acetaldehyde-mediated cardiomyocyte mitochondrial dysfunction in alcoholic cardiomyopathy","volume":"6","author":"Brandt","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.redox.2017.06.009_bib76","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbrc.2007.12.089","article-title":"ALDH-2 deficiency increases cardiovascular oxidative stress--evidence for indirect antioxidative properties","volume":"367","author":"Wenzel","year":"2008","journal-title":"Biochem Biophys. Res. Commun."},{"key":"10.1016\/j.redox.2017.06.009_bib77","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/bph.12081","article-title":"Tolerance to nitroglycerin through proteasomal down-regulation of aldehyde dehydrogenase-2 in a genetic mouse model of ascorbate deficiency","volume":"168","author":"Wolkart","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.redox.2017.06.009_bib78","first-page":"451","article-title":"Animal models in type 2 diabetes research: an overview","volume":"125","author":"Srinivasan","year":"2007","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.redox.2017.06.009_bib79","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1055\/s-0034-1395609","article-title":"Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis","volume":"47","author":"Ojima","year":"2015","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.redox.2017.06.009_bib80","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/dom.12073","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes","volume":"15","author":"Heise","year":"2013","journal-title":"Diabetes, Obes. Metab."},{"key":"10.1016\/j.redox.2017.06.009_bib81","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.2337\/db16-0058","article-title":"The Na+\/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels","volume":"65","author":"Hawley","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.redox.2017.06.009_bib82","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.redox.2017.06.009_bib83","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1868-7083-5-15","article-title":"Global differences in specific histone H3 methylation are associated with overweight and type 2 diabetes","volume":"5","author":"Jufvas","year":"2013","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.redox.2017.06.009_bib84","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.2337\/db08-0645","article-title":"Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes","volume":"57","author":"Miao","year":"2008","journal-title":"Diabetes"}],"container-title":["Redox Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213231717303932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213231717303932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:24:13Z","timestamp":1784906653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213231717303932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":84,"alternative-id":["S2213231717303932"],"URL":"https:\/\/doi.org\/10.1016\/j.redox.2017.06.009","relation":{},"ISSN":["2213-2317"],"issn-type":[{"value":"2213-2317","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats","name":"articletitle","label":"Article Title"},{"value":"Redox Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.redox.2017.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}